Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
This announcement reaffirms the Scottish Medicines Consortium’s decision of 10 February 2025, meaning that no disease-modifying therapies for Alzheimer’s disease are currently approved for use in Scotland.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.
The ADI Council met on 30 March 2021 to discuss ADI's activities over 2020, new membership applications and more.
Phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease.
The discussions focused on developing a regional policy brief for the promotion, protection and restoration of mental health in older adults, with the inclusion of a focus on dementia awareness and risk reduction.
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.